A complete set of laboratory investigations, including bleeding time, PFA-100 closure times, factor VIII (FVIII) coagulant activity (FVIII:C), von Willebrand factor (VWF) ristocetin cofactor (VWF:RCo), collagen binding (VWF:CB), antigen (VWF:Ag) and propeptide (VWFpp), ristocetin-induced platelet aggregation (RIPA), multimeric analysis of VWF and the response of FVIII:C and VWF parameters to desmopressin (DDAVP), is necessary to fully diagnose all variants of von Willebrand disease (VWD) and to discriminate between type 1 and type 2 and between severe VWD type 1 and type 3. The response to DDAVP of VWF parameters is normal in pseudo VWD (mild VWF deficiency due to blood group O), in mild VWD type 1 and in carriers of recessive severe VWD type 1 and 3. The response to DDAVP is rather good but restricted followed by increased clearance in dominant type 1/2E, good but transient in mild type 2A group II, good for VWF:CB, with only poor response for VWF:RCo in 2M and 2U, poor in 2A group I, 2B, 2C and 2D, and very poor or non-responsive in severe recessive VWD type 1 and 3. Homozygosity or double heterozygosity for nonsense (null) mutations in the VWF gene result in recessive VWD type 3. The combination of a nonsense and missense mutation or of two missense mutations (homozygous or double heterozygous) may cause recessive severe VWD type 1. Recessive VWD type 2A subtype IIC (2C) is caused by homozygous or double heterozygous gene defects in the D1–D2 domain. Homozygosity or double heterozygosity for a FVIII binding defect of the VWF is the cause of recessive VWD type 2N (Normandy) characterized by low FVIII:C, mild or moderate VWF deficiency and normal VWF multimers. Dominant VWD type 1/2E is a mixed quantitative and qualitative multimerization defect caused by a heterozygous cysteine mutation in the D3 domain resulting in abnormal multimerization with a secretion and clearance defect of VWF not due to increased proteolysis. Dominant VWD type 1 Vicenza is a qualitative defect with normal secretion but rapid clearance with equally low levels of FVIII:C, VWF:Ag, VWF:RCo, VWF:CB and the presence of unusually large VWF multimers in plasma due to a specific mutation (R1205H) in the D3 domain. Dominant VWD type 2M and 2U are caused by loss-of-function mutations in the A1 domain resulting in quantitative/qualitative deficiencies with a selectively decreased platelet-dependent function with decreased VWF:RCo but normal VWF:CB, a relative decrease in large VWF multimers and the presence but relative loss of large VWF multimers. VWD type 2A and 2B show loss of large VWF multimers due to increased proteolysis. Dominant type 2A is caused by heterozygous missense mutations in the A2 domain. VWD type 2B is due to gain-of-function mutations in the A1 domain and differs from 2A by a normal VWF multimeric pattern in platelets and increased RIPA. DDAVP response curves and VWFpp/Ag ratios contribute to the diagnostic differentiation of VWD type 1 and 2. Rapid clearance of VWF after DDAVP with increased VWFpp/Ag ratios >10 appears to be diagnostic for VWD Vicenza. VWD type 1/2E due to the mutations in the D3 domain uniformly show increased VWFpp/Ag ratios ranging from 3.2 to 4.69 indicating clearance of the VWF/FVIII complex. Normal VWFpp/Ag ratios in mild VWD type 1 with mutations in the D1-D2 and the D4-B-C domains reflect a synthesis/secretion defect.

Keywords:
Classification of von Willebrand disease, Dominant disease, International Society on Thrombosis and Haemostasis, Laboratory parameters, Molecular classification, Recessive disease, von Willebrand factor
1.
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet HHDM: Characterization of recessive severe type 1 and 3 von Willebrand disease (VWD), asymptomatic heterozygous carriers versus blood group O-related von Willebrand factor deficiency and dominant type 1 VWD. Clin Appl Thromb Hemost 2006;12:277–295.
2.
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet HHDM: Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin Appl Thromb Hemost 2006;12:397–420.
3.
Ruggeri ZM: Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001;14:257–279.
4.
Schneppenheim R, Budde U, Ruggeri ZM: A molecular approach to the classification of von Willebrand disease. Best Pract Res Clin Haematol 2001;14:281–298.
5.
Ruggeri ZM, Pareti FI, Mannnucci PM, Ciavarella N, Zimmerman TS: Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980;302:1047–1051.
6.
Zimmermann ThS, Dent JA, Ruggeri ZM, Nannini LH: Subunit composition of plasma von Willebrand factor. J Clin Invest 1986;77:947–951.
7.
Schneppenheim R, Budde U: Phenotypic and genotypic diagnosis of von Willebrand disease. Semin Hematol 2005;42:15–28.
8.
Sadler JE: A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994;71:520–525.
9.
Sadler JE, Mannucci PM, Bentorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A: Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–174.
10.
Sadler JE, Budde U, Eikenboom, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, Working Party on von Willebrand Disease Classification: Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006;4:2103–2114.
11.
Schneppenheim R, Krey S, Bergmann F, Bock D, Budde U, Lange M, Linde R, Mittler U, Meili E, Mertes G, Olek K, Plendl H, Simeoni E: Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994;94:640–652.
12.
Zhang ZP, Blomback M, Egberg N, Falk G, Anvret M: Characterization of the von Willebrand factor gene in von Willebrand disease type III patients from 24 families of Swedish and Finnish origin. Genomics 1994;21:188–193.
13.
Zhang A, Lindstedt M, Blomback M: Effects of the mutant von Willebrand factor gene in von Willebrand disease. Hum Genet 1995;96:388–394.
14.
Eikenboom JCJ, Castaman G, Vos HL, Bertina RM, Rodeghiero F: Characterization of genetic defects in recessive type 1 and type 3 von Willebrand patients of Italian origin. Thromb Haemost 1998;79:709–717.
15.
Baronciani L, Cozzi G, Cabciani MT, Peyandi F, Scrivastava A, Federici AB, Mannucci PM: Molecular characterization of a multi-ethnic group of 21 patients with type 3 von Willebrand disease. Thromb Haemost 2000;84:536–540.
16.
Eikenboom JCJ: Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001;14:365–379.
17.
Batlle J, López Fernández MF, Fernández Villamor A, López Berges CC, Zimmerman ThS: Multimeric pattern discrepancy between platelet and plasma von Willebrand factor in type IIC von Willebrand disease. Am J Hematol 1986;22:87–88.
18.
Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, Ingerslev J, Goodeve A, Peak IR, Daly ME: A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood 2000;96:560–568.
19.
Castaman G, Lattuada A, Mannucci PM, Rodeghiero F: Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol 1995;89:147–151.
20.
Castaman G, Eikenboom JCJ, Lattuada A, Manucci PM, Rodeghiero F: Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2364F mutation. Br J Haematol 2000;108:188–190.
21.
Castaman G, Novella E, Castiglia E, Eikenboom JCJ, Rodeghiero F: A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. Thromb Res 2002;105:135–138.
22.
Tjernberg P, Castaman G, Vos HL, Bertina RM, Eikenboom JCJ: Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor in autosomal recessive severe von Willebrand disease. Br J Haematol 2006;133:409–418.
23.
Castaman G, Bertoncello K, Bernardi M, Eikenboom JC, Budde U, Rodeghiero F: Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908delC) and the missense mutation C2362F: definite evidence for non-penetrance of the C2363F mutation. Am J Hematol 2007;82:376–380.
24.
Schneppenheim R, Budde U, Obser T, Brassard J, Mainush K, Ruggeri ZM, Schneppenheim S, Schwaab R, Oldenburg J: Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001;97:2059–2066.
25.
Ruggeri ZA, Nilsson IM, Lombardi R, Holmberg L, Zimmerman ThS: Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand’s disease (type IIC). J Clin Invest 1982;70:1124–1127.
26.
Holmberg L, Karpman D, Isakson C, Kristofferson AC, Lethagen S, Schneppenheim R: Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand’s disease. Thromb Haemost 1998;79:718–722.
27.
Mazurier C, Mannucci PM, Parquet-Gernez A, Goudemand M, Meyer D: Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype. Am J Hematol 1986;22:301–311.
28.
Gaucher C, Diéval J, Mazurier C: Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease. Blood 1994;84:1024–1030.
29.
Batlle J, Lopez-Fernandez MF, Lasiera J, Fernandez Villamor AF, Lopez Berges C, Lopez Borrasca A, Ruggeri ZM, Zimmerman ThS: von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibship. Am J Hematol 1986;21:177–188.
30.
University of Sheffield: ISTH SSC VWF Database. http://www.vwf.group.shef.ac.uk/index.html
31.
Schneppenheim R, Thomas KB, Krey S, Budde U, Jessat U, Sutor AH, Zieger B: Identification of a candidate missense mutation in a family with von Willebrand disease type IIC. Hum Genet 1995;95:681–686.
32.
Mazurier C, Goudemand J, Hilbert L, Caron C, Fressinaud E, Myer D: Type 2N von Willebrand disease. Best Pract Res Clin Haematol 2001;14:337–347.
33.
Mazurier C, Gaucher C, Jorieux S, Goudemand M: Biological effect of desmopressin in eight patients with type 2N (Normandy) von Willebrand disease. Br J Haematol 1994;88:849–854.
34.
Caron C, Mazurier C, Goudemand J: Large experience with factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol 2002;117:716–718.
35.
Jacquemin M, Lavend’homme R, Benhida A, Vanzieleghem B, d’Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Chuah MK, Hoylaerts M, Gilles JG, Peerlinck K, Vermylen J, Saint-Remy JM: A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor binding to von Willebrand factor. Blood 2000;96:958–965.
36.
Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, Goodeve AC, Gursel T, Ingerslev J, Peake IR, Daly ME: Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000;95:2000–2007.
37.
Joriuex S, Fressinaud E, Goudemand J, Gaucher C, Meyer D, Mazurier C: Conformational changes in the D’domain of von Willebrand factor induced by CYS 25 and CYS 95 mutations lead to factor VIII binding defect and multimeric impaiment. Blood 2000;95:3130–3145.
38.
Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U: Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost 2004;92:36–41.
39.
Casonato A, Sartorello F, Cattini MG, Pontera E, Soldera C, Bertomoro A, Girolami A: An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003;101:151–156.
40.
Hilbert L, Nurden P, Caron C, Nurden AT, Goudemand J, Myer D, Fressinaud E, Mazurier C: Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost 2006;96:290–294.
41.
Casana P, Martinez F, Haya S, Espinos C, Aznar JA: Association of the T1156M mutation in the von Willebrand factor gene with dominant type 1 von Willebrand disease. Ann Hematol 2001;80:381–383.
42.
Lethagen S, Isaksson C, Schaedel C, Holmberg L: von Willebrand disease caused by compound heterozygosity for a substitution mutation (T1156M) in the D3 domain of the von Willebrand factor and a stop mutation (Q2470X). Thromb Haemost 2002;88:421–426.
43.
Eikenboom JCJ, Matsushita T, Reitsma PH, Tuley E, Castaman G, Briët E, Sadler FE: Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor. Blood 1996;88:2433–2441.
44.
Castaman G, Eikenboom JCJ, Missiaglia E, Rodeghiero F: Autosomal dominant type 1 von Willebrand disease due to C1130F mutation in exon 26 of von Willebrand factor gene: description of five families and evidence for a founder effect. Br J Haematol 2000;108:876–879.
45.
Tjenberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JCJ: Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004;2:257–265.
46.
James PD, O’Brien LA, Hegadorn CA, Notley CRP, Sinclair GD, Huogh C, Poon MC, Lillicrap D: A novel type 2A von Willebrand factor mutation located at the last nucleotide of exon 26 (3538G→A) causes skipping of 2 nonadjacent exons. Blood 2004;104:2739–2745.
47.
Budde U, Schneppenheim R, Eikenboom JCJ, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I: Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008;6:762–771.
48.
Goodeve A, Eikenboom JCJ, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake I: Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007;109:112–121.
49.
Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero F: Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1VWD. Blood 2008;111:3531–3539.
50.
Schneppenheim R, Lenk H, Obser T, Oldenburg J, Oyen F, Schneppenheim S, Schwaab R, Will K, Budde U: Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding defect and multimerization. Thromb Haemost 2004;92:36–41.
51.
Casonato A, Sartorello F, Cattini MG, Pontera E, Soldera C, Bertomoro A, Girolami A: An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003;101:151–156.
52.
Hilbert L, Nurden P, Caron C, Nurden AT, Goudemand J, Myer D, Fressinaud E, Mazurier C: Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb Haemost 2006;96:290–294.
53.
Eikenboom JCJ, Castaman G, Kamphuizen PW, Rosendaal FR, Bertina RM: The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002;87:252–257.
54.
Michiels JJ, van Vliet HHDM, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, Budde U: Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleeding in patients with von Willebrand disease type 1, 2 and 3. Clin Appl Thromb Hemost 2007;13:14–34.
55.
d’Orion R, Lavergne JM, Lavend’homme R, Benhida A, Bordet JC, Negrier C, Peerlinck K, Vermylen J, Saint-Remy JM, Jacquemin M: Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004;103:155–157.
56.
Mannucci PM: Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia. 2000;6(suppl 1): 60–67.
57.
Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, Lethagen S, Nitu I, Ludwig G, Hilbert L, Mannucci PM: Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004;103:2032–2038.
58.
Michiels JJ, van de Velde A, van Vliet HHDM, van der Planken M, Schroyens W, Berneman Z: Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin Thromb Hemost 2002;28:111–131.
59.
Lethagen S, Harris AS, Sjorin E, Nilsson IM: Intranasal and intravenous administration of desmopressin: effect on FVIII/VWF, pharmacokinetics and reproducibility. Thromb Haemost 1987;58:1033–1036.
60.
Kohler M, Hellstern P, Tarrach H, Bambauer R, Wenzel E, Jutzler GA: Subcutaneous injection of desmopressin (DDAVP): evaluation of a new, more concentrated preparation. Haemostasis 1989;19:38–44.
61.
Casonato A, Pontara E, Sartorello F, Cattini MG, Sartoei MT, Padrini R, Girolami A: Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002;99:180–184.
62.
Casonato A, Pontara E, Sartorelli F, Cattini MG, Gallinaro L, Bertomoro A, Rosato A, Padrini R, Pagnan A: Identifying type Vicenza von Willebrand disease. J Lab Clin Med 2006;147:96–101.
63.
Vischer UM, Wagner DD: von Willebrand proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994;83:3536–3544.
64.
Hannah MJ, Williams R, Kaur J, Hewlett LJ, Cutler DF: Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol 2002;13:313–324.
65.
Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, Pasterkamp G, Meijer-Huizinga F, Zwart-Hunink L, Voorberg J, van Mourik JA: Quantitative analysis of von Willebrand propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996;88:2951–2958.
66.
Huang RH, Wang Y, Roth R, Yu X, Purvis AR, Heuser JE, Egelman EH, Sadler JF: Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor. Proc Natl Acad Sci USA 2008;105:482–487.
67.
Haberichter SL, Balistrieri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR: Assay of von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006;108:3344–3351.
68.
Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR: Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propetide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD (MCMDM-1VWD). Blood 2008;111:4979–4985.
69.
Davies JA, Collins PW, Hathaway LS, Bowen DJ: von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 2008;6:97–103.
70.
Sztukowska M, Gallinaro L, Cattini MG, Pontara E, Sartorello F, Diadone V, Padrini R, Pagnan A, Casonato A: von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Brit J Haematol 2008;143:107–114.
71.
Millar CM, Riddell AF, Brown SA, Starke R, Mackie I, Bowen DJ, Jenkins PV, van Mourik JA: Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycolysation, proteolysis and gene mutations. Thromb Haemost 2008;99:916–924.
72.
Mannucci PM, Aberg M, Nilsson IM, Robertson B: Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30:81–93.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.